NEOM has signed a strategic memorandum of understanding with WuXi AppTec, one of the world’s leading companies in contract research, development, and manufacturing services in the pharmaceutical industry.
Under the agreement, the two parties will collaborate to explore opportunities for localizing pharmaceutical research, development, and manufacturing capabilities in the Kingdom, SPA reported.
In the long term, the cooperation aims to establish a world-class contract development and manufacturing facility within OXAGON, NEOM’s clean and advanced industries city, or at other locations across Saudi Arabia.
In support of the Kingdom’s strategies for economic diversification and innovation, the MoU represents a major step toward realizing national ambitions in the biotechnology sector and reflects a shared commitment to driving sustainable growth in the pharmaceutical and healthcare sectors.
This partnership embodies the convergence of global expertise and the Kingdom’s visionary leadership in building an advanced biopharmaceutical manufacturing ecosystem. It marks a significant move toward creating a fully integrated industrial environment serving regional and global markets, leveraging OXAGON’s clean-industry framework and WuXi AppTec’s leading capabilities in pharmaceutical innovation.
The agreement highlights a strategic and intellectual alignment between two pioneering entities: WuXi AppTec’s global experience in advancing biopharmaceutical innovation, and NEOM’s pivotal role as a key enabler of Saudi Arabia’s National Biotechnology Strategy under Vision 2030.
Through this collaboration, both sides aim to chart new pathways that contribute to the Kingdom’s long-term goals and set a new global benchmark for cooperation in pharmaceutical innovation.
